Premium
Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study
Author(s) -
Belalcazar L. Maria,
Haffner Steven M.,
Lang Wei,
Hoogeveen Ron C.,
Rushing Julia,
Schwenke Dawn C.,
Tracy Russell P.,
PiSunyer F. Xavier,
Kriska Andrea M.,
Ballantyne and the Look AHEAD Action for Health in Diabetes Research Group Christie M.
Publication year - 2013
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.20431
Subject(s) - medicine , overweight , statin , type 2 diabetes , randomized controlled trial , c reactive protein , weight loss , diabetes mellitus , obesity , physical therapy , simvastatin , endocrinology , inflammation
Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was −44.9 and −42.3%, respectively, compared to −13.7 and −21.0% for those on statins and usual care ( P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L −1 in participants randomized to ILI on statin therapy; 2.6 mg L −1 for those on statins randomized to usual care and 2.9 mg L −1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction ( P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits.